Shattuck Labs (STTK) Net Income towards Common Stockholders (2019 - 2026)

Shattuck Labs (STTK) reported Net Income towards Common Stockholders of -$14.8 million for Q1 2026, down 7.78% year-over-year from -$16.0 million in Q1 2025, and down 10.43% quarter-over-quarter from -$13.4 million in Q4 2025.

Shattuck Labs (STTK) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends

Shattuck Labs (STTK) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$14.8 million in Q1 2026.

  • Net Income towards Common Stockholders for Q1 2026 came in at -$14.8 million, down 7.78% year-over-year; the trailing twelve-month figure through Mar 2026 was -$51.9 million (up 30.1% YoY), and the FY2025 annual result was -$48.8 million, up 35.27% from the prior year.
  • Net Income towards Common Stockholders eased to -$14.8 million in Q1 2026 per STTK's latest filing, from -$13.4 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at -$10.7 million in Q3 2025 and troughed at -$28.6 million in Q3 2023.
  • A 5-year average of -$20.1 million and a median of -$20.0 million in 2024 frame the typical range for Net Income towards Common Stockholders.
  • The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders slumped 431.6% in 2022, then jumped 43.25% in 2025.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$26.3 million in 2022, then grew by 27.88% to -$19.0 million in 2023, then fell by 3.64% to -$19.6 million in 2024, then surged by 31.92% to -$13.4 million in 2025, then dropped by 10.43% to -$14.8 million in 2026.
  • Business Quant data shows STTK's Net Income towards Common Stockholders at -$14.8 million in Q1 2026, -$13.4 million in Q4 2025, and -$10.7 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -26.94 Mn
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -13.56 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 2.50 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -3.63 Mn
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -14.46 Mn
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -1.50 Mn
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 1.03 Bn
9 Abivax 91.96 Bn 91.96 Bn - -56.48 Mn
10 Shattuck Labs 190.32 Mn 190.32 Mn - -14.77 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -14.77 Mn
Dec 31, 2025 -13.37 Mn
Sep 30, 2025 -10.72 Mn
Jun 30, 2025 -13.03 Mn
Mar 31, 2025 -13.70 Mn
Dec 31, 2024 -19.64 Mn
Sep 30, 2024 -17.92 Mn
Jun 30, 2024 -22.96 Mn
Mar 31, 2024 -20.04 Mn
Dec 31, 2023 -18.95 Mn
Sep 30, 2023 -28.60 Mn
Jun 30, 2023 -22.75 Mn
Mar 31, 2023 -21.66 Mn
Dec 31, 2022 -26.28 Mn
Sep 30, 2022 -25.23 Mn
Jun 30, 2022 -27.66 Mn
Mar 31, 2022 -24.17 Mn
Dec 31, 2021 7.92 Mn
Sep 30, 2021 -17.33 Mn
Jun 30, 2021 -23.51 Mn